Joint development and sales agreement with Asuka Pharmaceutical for a therapeutic app in the obstetrics and gynecology field
First written in FY2023. 7 of 9 entries say "Advanced", first in FY2024-Q1. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「For the therapeutic app targeting premenstrual syndrome and premenstrual dysphoric disorder being jointly developed with あすか製薬株式会社, the company received a ¥100 million milestone payment after effective results anticipated in the specified clinical research were confirmed. It plans to receive total milestone revenue of up to ¥2.3 billion depending on the development stage and other factors, and plans to receive royalties based on sales after the product is launched.」
For the app being developed with あすか製薬株式会社, effective results were confirmed in specified clinical research and a ¥100 million milestone payment was received. The parties agreed to proceed to the next development stage, raising the cap on future milestones to ¥2.3 billion. - FY2026-H1AdvancedAnnual report
「For the therapeutic app for premenstrual syndrome and premenstrual dysphoric disorder being jointly developed with Aska Pharmaceutical Co., Ltd., subject enrollment in the specified clinical research study has been completed. The Company expects to receive up to ¥2.4 billion in total milestone payments based on future development stages, as well as royalties based on sales after product launch.」
For the app for premenstrual syndrome and premenstrual dysphoric disorder being developed with Aska Pharmaceutical, subject enrollment in the specified clinical research study has been completed. The framework for milestone payments of up to ¥2.4 billion and post-launch royalties remains in place. - FY2025-H1AdvancedAnnual report
「In the therapeutic app for premenstrual syndrome and premenstrual dysphoric disorder being jointly developed with Aska Pharmaceutical Co., Ltd., the Company commenced a specified clinical research study and achieved a milestone when the first subject began using the app. Accordingly, the Company expects to receive ¥100 million in development milestone payments stipulated in the agreement with Aska Pharmaceutical Co., Ltd. covering the joint research and development and sale of a therapeutic app in obstetrics and gynecology. The Company expects to receive up to ¥2.4 billion in total milestone payments based on future development stages, as well as royalties based on sales after product launch.」
The Company commenced specified clinical research for the app for premenstrual syndrome and premenstrual dysphoric disorder and achieved a ¥100 million development milestone when the first subject began using the app. The maximum total of future milestone payments has changed from ¥2.5 billion to ¥2.4 billion. - FY2024-Q2AdvancedAnnual report
「In addition, in September 2023, the Company entered into an agreement with Aska Pharmaceutical Co., Ltd. covering the joint research and development of a therapeutic app in obstetrics and gynecology and its sale after product launch, and received ¥200 million as an upfront payment. The Company expects to receive up to ¥2.5 billion in total milestone payments based on future development stages, as well as royalties based on sales after product launch.」
Under the therapeutic app agreement with Aska Pharmaceutical in obstetrics and gynecology, the Company received a ¥200 million upfront payment. The framework for milestone payments of up to ¥2.5 billion and post-launch royalties remains in place. - FY2024-Q1AdvancedAnnual report
「In addition, in September 2023, the Company entered into an agreement with Aska Pharmaceutical Co., Ltd. covering the joint research and development of a therapeutic app in obstetrics and gynecology and its sale after product launch. The Company expects to receive ¥200 million as an upfront payment and up to ¥2.5 billion in total milestone payments based on future development stages, as well as royalties based on sales after product launch.」
The terms of the therapeutic app agreement with Aska Pharmaceutical in obstetrics and gynecology were disclosed, including its execution in September 2023, a ¥200 million upfront payment, milestone payments of up to ¥2.5 billion, and post-launch royalties. - FY2023First statedAnnual report
「At a meeting of the Board of Directors held on 21 September 2023, the Company resolved to enter into an agreement with Aska Pharmaceutical Co., Ltd. covering the joint research and development of a therapeutic app in obstetrics and gynecology and its sale after product launch (the “Agreement”), and entered into the Agreement as of 25 September 2023.」
The execution of an agreement with Aska Pharmaceutical for the joint research and development and post-launch sale of a therapeutic app in obstetrics and gynecology was disclosed as a subsequent event.